US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SKHY $195.02 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00% INTC $116.19 ▲+0.00% AVGO $362.51 ▲+0.00%
FinancialContent

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
41 42 Next >
News headline image
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
  
Via Benzinga
Study Suggests LSD May Boost Learning, Memory by Enhancing Neural Plasticity
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From August 17, 2022 ↗
  
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Partner Receive Required Schedule I License from DEA for First-in-Human Clinical Trial
Via Investor Brand Network
News headline image
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression ↗
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S. 
Via Benzinga
News headline image
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
From Cybin Inc.
Via Business Wire
News headline image
Psychedelic Stock Gainers And Losers From August 16, 2022 ↗
  
Via Benzinga
News headline image
These Depression Players Are Top Picks For $400B Mental Healthcare Market, Says Analyst ↗
HC Wainwright expects COMPASS Pathways Plc (NASDAQ: CMPS) and Cybin Inc (NYSE: CYBN) to be leaders in the emerging $400 billion mental healthcare market. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders
Via Investor Brand Network
News headline image
Cybin Announces Results of Shareholders’ Meeting
From Cybin Inc.
Via Business Wire
News headline image
Allied, Cybin Among Top Psychedelic Movers Of Today ↗
  
Via Benzinga
News headline image
Major Psychedelic Stocks Down This Week; Still Up Since End Of June ↗
The 8 stocks in our Psychedelic Compounds-Based Drug Stocks Index dropped 8.4% this week for the first time in 5 weeks but are still up 45.3% since then. 
Via Talk Markets
News headline image
Mind Medicine, Numinus Wellness Among Top Psychedelic Movers From Today ↗
  
Via Benzinga
Psilocybin Lawsuit Filed in Canada May Boost Global Psychedelics Reform Efforts
Via Investor Brand Network
Topics Lawsuit
News headline image
Compass Pathways, Revive Therapeutics Among Top Psychedelic Movers Of Today ↗
  
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From August 10, 2022 ↗
  
Via Benzinga
Brain Fingerprinting Adolescents Could Predict Future Mental-Health Issues
Via Investor Brand Network
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study... 
Via FinancialNewsMedia
Topics Supply Chain
News headline image
3 Best Psychedelic Stocks to Buy Now ↗
These are three of the best psychedelic stocks to buy to get in on the next generation of treatment for mental health disorders. 
Via InvestorPlace
News headline image
This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares ↗
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) has launched an at-the-market (ATM) equity program through which it will issue and sell up to $35 million in common shares in the company’s capital, from the... 
Via Benzinga
News headline image
Cybin, Field Trip Health Among Top Psychedelic Movers Of Today ↗
  
Via Benzinga
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report
Via Investor Brand Network
Topics Intellectual Property
News headline image
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
From Cybin Inc.
Via Business Wire
News headline image
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Toronto Firm Receives First Federal Government Funding to Study Psilocybin
Via Investor Brand Network
News headline image
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6... 
Via Benzinga
News headline image
GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 29.83% at $15.80 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From August 4, 2022 ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 10.64% at $12.17 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program
Via Investor Brand Network
New Poll Finds Most Americans Support Research on Psychedelics for Military Members
Via Investor Brand Network
Topics Cannabis
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
41 42 Next >